company background image
ANIX

Anixa Biosciences NasdaqCM:ANIX Stock Report

Last Price

US$3.37

Market Cap

US$101.6m

7D

-7.7%

1Y

-9.4%

Updated

15 May, 2022

Data

Company Financials +
ANIX fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

ANIX Stock Overview

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases.

Anixa Biosciences Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Anixa Biosciences
Historical stock prices
Current Share PriceUS$3.37
52 Week HighUS$5.87
52 Week LowUS$2.30
Beta1.41
1 Month Change28.63%
3 Month Change11.96%
1 Year Change-9.41%
3 Year Change-21.08%
5 Year Change237.00%
Change since IPO-96.04%

Recent News & Updates

May 11

Anixa: Making Sense Of A Bullish Move Up In Bearish Biotech Times

Anixa Biosciences has different very interesting programs ongoing, one of which is a breast cancer vaccine trial with a first partial readout at ASCO in the beginning of June. While the biotech sector has been suffering large losses over the past month, Anixa Biosciences shares have moved up remarkably. Trial enrollment for the vaccine trial was fast, and the company seems optimistic about the near-term future of the company. The market is huge, and if the trial is successful, chances are we are seeing the beginning of a huge spike in share price. 2022 will, in any case, be the year for Anixa, with other programs ongoing as well.

Feb 24
We're Interested To See How Anixa Biosciences (NASDAQ:ANIX) Uses Its Cash Hoard To Grow

We're Interested To See How Anixa Biosciences (NASDAQ:ANIX) Uses Its Cash Hoard To Grow

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Shareholder Returns

ANIXUS BiotechsUS Market
7D-7.7%0.1%-2.5%
1Y-9.4%-21.7%-10.4%

Return vs Industry: ANIX exceeded the US Biotechs industry which returned -21.7% over the past year.

Return vs Market: ANIX matched the US Market which returned -10.4% over the past year.

Price Volatility

Is ANIX's price volatile compared to industry and market?
ANIX volatility
ANIX Average Weekly Movement11.0%
Biotechs Industry Average Movement12.3%
Market Average Movement7.8%
10% most volatile stocks in US Market16.7%
10% least volatile stocks in US Market2.8%

Stable Share Price: ANIX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: ANIX's weekly volatility (11%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19825Amit Kumarhttps://www.anixa.com

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company’s therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer.

Anixa Biosciences Fundamentals Summary

How do Anixa Biosciences's earnings and revenue compare to its market cap?
ANIX fundamental statistics
Market CapUS$101.61m
Earnings (TTM)-US$14.58m
Revenue (TTM)n/a

9,999x

P/S Ratio

-7.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ANIX income statement (TTM)
Revenue-US$500.00
Cost of RevenueUS$2.00
Gross Profit-US$502.00
Other ExpensesUS$14.57m
Earnings-US$14.58m

Last Reported Earnings

Jan 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.48
Gross Margin100.40%
Net Profit Margin2,915,080.00%
Debt/Equity Ratio0%

How did ANIX perform over the long term?

See historical performance and comparison

Valuation

Is Anixa Biosciences undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


2.99x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ANIX's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ANIX's fair value for valuation analysis.


Price To Earnings Ratio

PE vs Industry: ANIX is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: ANIX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ANIX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ANIX is overvalued based on its PB Ratio (3x) compared to the US Biotechs industry average (1.4x).


Future Growth

How is Anixa Biosciences forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


-18.6%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ANIX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ANIX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ANIX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ANIX is forecast to have no revenue next year.

High Growth Revenue: ANIX is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ANIX's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Anixa Biosciences performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-10.0%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: ANIX is currently unprofitable.

Growing Profit Margin: ANIX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ANIX is unprofitable, and losses have increased over the past 5 years at a rate of 10% per year.

Accelerating Growth: Unable to compare ANIX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ANIX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).


Return on Equity

High ROE: ANIX has a negative Return on Equity (-44.45%), as it is currently unprofitable.


Financial Health

How is Anixa Biosciences's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: ANIX's short term assets ($35.0M) exceed its short term liabilities ($1.8M).

Long Term Liabilities: ANIX's short term assets ($35.0M) exceed its long term liabilities ($209.0K).


Debt to Equity History and Analysis

Debt Level: ANIX is debt free.

Reducing Debt: ANIX currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ANIX has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: ANIX has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 8.4% each year


Dividend

What is Anixa Biosciences's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate ANIX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ANIX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ANIX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ANIX's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ANIX has not reported any payouts.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.8yrs

Average management tenure


CEO

Amit Kumar (57 yo)

4.83yrs

Tenure

US$10,959,086

Compensation

Dr. Amit Kumar, Ph.D. is a Director at Ascent Solar Technologies, Inc. since June 2007 and has been its Independent Chairman of the Board since January 2011. Dr. Kumar is the Chief Executive Officer at Ani...


CEO Compensation Analysis

Compensation vs Market: Amit's total compensation ($USD10.96M) is above average for companies of similar size in the US market ($USD770.21K).

Compensation vs Earnings: Amit's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: ANIX's management team is considered experienced (4.8 years average tenure).


Board Members

Experienced Board: ANIX's board of directors are considered experienced (3.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: ANIX insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Anixa Biosciences, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Anixa Biosciences, Inc.
  • Ticker: ANIX
  • Exchange: NasdaqCM
  • Founded: 1982
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$101.613m
  • Shares outstanding: 30.15m
  • Website: https://www.anixa.com

Number of Employees


Location

  • Anixa Biosciences, Inc.
  • 3150 Almaden Expressway
  • Suite 250
  • San Jose
  • California
  • 95118
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/15 00:00
End of Day Share Price2022/05/13 00:00
Earnings2022/01/31
Annual Earnings2021/10/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.